Company received a royalty-bearing license to the patent under consideration.
Watson Pharmaceuticals says that it reached a settlement with GlaxoSmithKline (GSK) on a patent litigation related to GSK’s antidepressant.
In December 2005, Andrx, now owned by Watson, filed a lawsuit in the U.S. District Court for the Southern District of Florida against GSK alleging that the 150-mg dose of Wellbutrin XL infringed Andrx’ patent.
Under terms of the settlement, Andrx will receive a one-time payment of $35 million. GSK also received a royalty-bearing license to the relevant patent.